Latest Breaking News On - பாலிசேட் உயிர் இன்க் - Page 1 : comparemela.com
Cerebral Palsy Market 2021 Valuable Growth Prospects and Upcoming Trends till 2028
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
North American Morning Briefing: Stock Futures -3-
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Best Penny Stocks To Buy On Robinhood Now? 12 To Watch This Week | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
FinancialBuzz.com’s latest
The Buzz Show: Palisade Bio, Inc. Announces FDA Fast Track Designation for its investigational drug LB1148”
Palisade Bio, Inc. (NASDAQ: PALI) surged over 25% in premarket trading after the company announced an FDA Fast Track Designation for the investigational drug LB1148.
LB1148 has the potential to be the first oral treatment to reduce adhesions following abdominal or pelvic surgery, and was previously granted Fast Track Designation for the treatment of postoperative GI dysfunction associated with gut hypoperfusion injury in pediatric patients who have undergone congenital heart disease repair surgery.
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore
LB1148 was previously granted Fast Track Designation to treat postoperative GI dysfunction associated with pediatric cardiovascular surgery.
Phase 2 gastrointestinal surgery trial that will evaluate LB1148 for reducing adhesions, is expected to read out data in 2021.
LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.
By inhibiting the activity of digestive proteases, LB1148 can potentially reduce damage to GI tissues, increase the time to return normal GI function, and shorten the duration of hospital stays.
Price Action: PALI shares are trading 26.1% higher at $6.62 during the premarket session on the last check Thursday.